DOCSLIB.ORG

Key Message Bulletin 9: Calcium Channel Blockers

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Key Message Bulletin 9: Calcium Channel Blockers + Medicines Optimisation Key Messages – Bulletin 9 Medicines Optimisation of CCBs 1 KEY MESSAGE: Prescribe generic amlodipine or lercanidipine first line • In Norfolk & Waveney CCGs amlodipine is a 1st line option1 when a calcium channel blocker (CCB) is indicated for hypertension or angina • Lercanidipine is an alternative 1st line option licensed for hypertension1,2 • They are both available generically in the UK and are relatively inexpensive compared with other dihydropyridine CCBs e.g. felodipine, lacidipine, nifedipine, nicardipine, isradipine • nd 1,2 The 2 choice CCB licensed for hypertension and angina is felodipine Regional Drugs & Therapeutics Centre (Newcastle) http://rdtc.nhs.uk/sites/default/files/cost-comparison-charts-oct-2015.pdf Anglia Prescribing & Medicines Management Team Version: 3.1 Issued: January 2016 Review date: January 2017 Reviewing Your Practice 1. Use generic amlodipine or generic lercanidipine* first line for newly treated patients as per licensed indications 2. Identify patients who have NOT tried amlodipine / lercanidipine* for hypertension and consider changing: a. Run a search to identify patients on felodipine or lacidipine, for hypertension (including brand names). b. Exclude those who have had amlodipine / lercanidipine previously c. Invite patient for a BP review, discuss with patient and consider suitability for switch to amlodipine – see table below for suggested dose equivalence3, 4 OR Write a letter to inform the selected patients of the drug switch d. Review BP after 4 weeks Suggested dose equivalence to amlodipine 5mg for hypertension3,4 Lercanidipine 10mg Lacidipine 2-4mg Felodipine M/R 5mg *For patients who also take simvastatin: use lercanidipine to avoid the interaction with amlodipine MHRA Aug 12 (maximum licensed simvastatin dose is 20mg with amlodipine due to increased risk of myopathy) Ankle oedema associated with CCBs • Ankle swelling is an adverse effect of all calcium-channel blockers. • It is not related to fluid retention, but possibly caused by increasing capillary pressure leading to leakage of fluids into the surrounding tissues. Diuretics therefore have little effect on CCB induced oedema. Treatment strategies include5: ♦ Non-pharmacological interventions i.e. elevation of legs or graduated compression stockings ♦ Dosage adjustment as oedema can be dose-related ♦ Adding an angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor antagonist (A2RA) if an ACEI cannot be tolerated. ♦ Switching to alternative CCB ♦ Discontinuation and switching to an antihypertensive from another class of drugs References: 1. NEL CSU (North,Norwich,South & West Norfolk CCGs) Cardiovascular Formulary accessed 14.12.15 nww.knowledgeanglia.nhs.uk/prescribing_nhsn/formulary/formulary_cardiovascular.pdf 2. Electronic Medicines Compendium accessed 14.12.15 www.medicines.org.uk/emc 3. UKMi Medicines Q&A What-are-appropriate-doses-to-use-when-switching-hypertensive-patients-to-amlodipine-from-lercanidipine-or-lacidipine? 10th May 2012 See link below 4. UKMi Medicines Q&A How-do-amlodipine-and-felodipine-compare-for-the-treatment-of-hypertension-or-prophylaxis-of-stable-angina ? 17th October 2012. See link below 5. UKMi Medicines Q&A How-should-ankle-oedema-caused-by-calcium-channel-blockers-be-treated? 14TH August 2013. See link below www.evidence.nhs.uk/Search?om=[{"srn":[" ukmi "]}]&q=calcium+channel+blockers Anglia Prescribing & Medicines Management Team Version: 3.1 Issued: January 2016 Review date: January 2017 Title KEY MESSAGES Bulletin 9- Medicines Optimisation of CCBs Description of policy To inform healthcare professionals Scope Prescribing info on Calcium Channel Blockers Prepared by Prescribing & Medicines Management Team (AA.LS.MC) Evidence base / Legislation Level of Evidence: A. based on national research-based evidence and is considered best evidence B. mix of national and local consensus C. based on local good practice and consensus in the absence of national research based information. Dissemination Is there any reason why any part of this document should not be available on the public web site? Yes / No Approved by NHSN&W Prescribing Reference Group 2/8/12 (version 1) Authorised by NHSN&W Drug & Therapeutics Commissioning Group 16/8/12 (version 1). Prescribing & Medicines Management Senior Team 19/11/13 (version 2),26.11.14 (V3.0), 25.2.16 (V3.1) Review date and by whom January 2017 Prescribing & Medicines Management Team Date of issue January 2016 Version Date Author Status Comment 0.1 5/4/12 Prescribing & Meds draft Man Team AA,LS 0.2 16/4/12 Prescribing & Meds draft Ref. added. Indications added to CCBs in key Man Team AA,LS,MC message. 0.3 22/5/12 Prescribing & Meds draft Replaced cost table with April 12 version Man Team AA LS,MC 0.4 28/6/12 Prescribing & M LS,MC draft Removed some CCBs from switch search and eds Man Team AA nifedipine from equivalence table. 0.5 13/7/12 Prescribing & Meds draft Updated following network group comments Man Team AA LS,MC 0.5 2/8/12 Prescribing & Meds draft Passed by Prescribing Ref Group Man Team AA LS 0.5 16/8/12 Prescribing & Meds draft Ratified by D & T Commissioning Group Man Team AA LS 1.0 5/9/12 Prescribing & Meds Final Man Team AA LS 1.1 9.9.13 Prescribing & Meds draft New format. Cost comparison update. Man Team MC Lercanidpine added as 1st line, ref to new CV formulary. Syntax changes to key messages. Clarification of which CCBs are dihydropyridines. Remove 2012 QIPP saving details. Reviewing practice box changed to include lercandipine as option to switch to. Approved by Prescribing & Medicines Management Senior Team. 19.11.13 2.0 20.11.13 Prescribing & Meds Final Man Team MC 2.1 6.11.14 Prescribing & Meds draft Logo changed . Ref to amlostin removed as 5mg Man Team MC no longer available. Cost table updated. Approved by Prescribing & Medicines Management Senior Team addition of information on interaction with amlodipine/simvastatin 2.2 19.11.14 Prescribing & Meds draft Section added for amlodipine/simvastatin Man Team MC interaction 2.3 24.11.14 Prescribing & Meds draft Further amendment of above interaction to use Man Team MC lercanidipine. Key Messages Bulletin Page 3 0f 4 ver 3.1 – January 2016 3.0 26.11.14 Prescribing & Meds final Approved by Senior Prescribing Team Man Team MC 3.1 14.12.15 Prescribing & Meds Draft Cost table updated. Slight syntax change. Man Team MC update Reference links checked and updated. Approved by Senior Prescribing Team 25.2.16 Key Messages Bulletin Page 4 0f 4 ver 3.1 – January 2016 .
Load more

Recommended publications
  • S Values in Accordance with Soczewiński-Wachtmeisters Equation
    S values in accordance with Soczewiński-Wachtmeisters equation S value from Antiparasitic drugs: Soczewiński’s Metronidazole Ornidazole Secnidazole Tinidazole Equation* S(m) 1.614 2.161 1.921 1.911 S(a) 1.634 2.159 1.887 1.923 S value from Antihypertensive drugs: Soczewiński’s Nilvadipine Felodipine Isradipine Lacidipine equation 4.129 4.597 3.741 5.349 S(m) S(a) 5.330 4.841 4.715 5.690 S value from Non-steroidal anti-inflammatory drugs (NSAIDs): Soczewiński’s Mefenamic Indomethacin Nabumetone Phenylbutazone Carprofen Ketoprofen Flurbiprofen equation acid 2.879 2.773 3.456 2.682 2.854 2.139 2.568 S(m) 3.317 3.442 3.910 2.404 3.394 1.968 2.010 S(a) *where: S(m) – S is the slope of the regression curie in accordance with Soczewiński-Wachtmeisters equation using methanol-water mobile phase S(a) – S is the slope of the regression curie in accordance with Soczewiński-Wachtmeisters equation using acetone-water mobile phase First group of drugs (antiparasitic drugs) 1. Metronidazole (2-Methyl-5-nitroimidazole-1-ethanol) 2. Ornidazole (1-(3-Chloro-2-hydroxypropyl)-2-methyl-5-nitroimidazole) 3. Secnidazole (1-(2-methyl-5-nitro-1H-imidazol-1-yl) propan-2ol, 1-(2Hydroxypropyl)-2-methyl-5- nitroimidazole) 4. Tinidazole (1-[2-(Ethylsulfonyl)ethyl]-2-methyl-5-nitroimidazole) Second group of drugs (antihypertensive drugs) 1. Nilvadipine (2-Cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3- methyl 5-(1-methylethyl) ester, 5-Isopropyl-3-methyl-2-cyano-1,4-dihydro-6-methyl-4-(m- nitrophenyl)-3,5-pyridinedicarboxylate, FK-235, FR-34235, Isopropyl 6-cyano-5-methoxycarbonyl-2- methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate) 2.
    [Show full text]
  • Investigating the Influence of Polymers on Supersaturated
    Page 1 of 45 Molecular Pharmaceutics 1 2 3 4 5 6 7 Investigating the Influence of Polymers on 8 9 10 11 12 Supersaturated Flufenamic Acid Cocrystal Solutions 13 14 15 16 1 1 2 2 1 17 Minshan Guo , Ke Wang , Noel Hamill , Keith Lorimer and Mingzhong Li * 18 19 20 1School of pharmacy, De Montfort University, Leicester, UK 21 22 23 2Almac Science, Seagoe Industrial Estate, Craigavon, UK 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ACS Paragon Plus Environment 1 Molecular Pharmaceutics Page 2 of 45 1 2 3 4 5 6 7 Table of contents graphic 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ACS Paragon Plus Environment 2 Page 3 of 45 Molecular Pharmaceutics 1 2 3 Abstract 4 5 6 7 The development of enabling formulations is a key stage when demonstrating the effectiveness 8 9 10 of pharmaceutical cocrystals to maximize the oral bioavailability for poorly water soluble drugs. 11 12 Inhibition of drug crystallization from a supersaturated cocrystal solution through a fundamental 13 14 understanding of the nucleation and crystal growth is important. In this study, the influence of 15 16 17 the three polymers of polyethylene glycol (PEG), polyvinylpyrrolidone (PVP) and a copolymer 18 19 of N-vinly-2-pyrrodidone (60%) and vinyl acetate (40%) (PVP-VA) on the flufenamic acid 20 21 22 (FFA) crystallization from three different supersaturated solutions of the pure FFA and two 23 24 cocrystals of FFA-NIC CO and FFA-TP CO has been investigated by measuring nucleation 25 26 induction times and desupersaturation rates in the presence and absence of seed crystals.
    [Show full text]
  • PACKAGE LEAFLET: INFORMATION for the USER Lercanidipine
    PACKAGE LEAFLET: INFORMATION FOR THE USER Lercanidipine Hydrochloride 10 mg Film-coated Tablets Lercanidipine Hydrochloride 20 mg Film-coated Tablets lercanidipine hydrochloride Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any of the side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Lercanidipine Hydrochloride Film-coated Tablets is and what it is used for 2. What you need to know before you take Lercanidipine Hydrochloride Film-coated Tablets 3. How to take Lercanidipine Hydrochloride Film-coated Tablets 4. Possible side effects 5. How to store Lercanidipine Hydrochloride Film-coated Tablets 6. Contents of the pack and other information 1. WHAT LERCANIDIPINE HYDROCHLORIDE FILM-COATED TABLETS IS AND WHAT IT IS USED FOR Lercanidipine belongs to a group of medicines called calcium channel blockers (dihydropyridine derivatives) that lower blood pressure.. Lercanidipine is used to treat high blood pressure also known as hypertension in adults over the age of 18 years (it is not recommended for children under 18 years old). 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE LERCANIDIPINE
    [Show full text]
  • Optum Essential Health Benefits Enhanced Formulary PDL January
    PENICILLINS ketorolac tromethamineQL GENERIC mefenamic acid amoxicillin/clavulanate potassium nabumetone amoxicillin/clavulanate potassium ER naproxen January 2016 ampicillin naproxen sodium ampicillin sodium naproxen sodium CR ESSENTIAL HEALTH BENEFITS ampicillin-sulbactam naproxen sodium ER ENHANCED PREFERRED DRUG LIST nafcillin sodium naproxen DR The Optum Preferred Drug List is a guide identifying oxacillin sodium oxaprozin preferred brand-name medicines within select penicillin G potassium piroxicam therapeutic categories. The Preferred Drug List may piperacillin sodium/ tazobactam sulindac not include all drugs covered by your prescription sodium tolmetin sodium drug benefit. Generic medicines are available within many of the therapeutic categories listed, in addition piperacillin sodium/tazobactam Fenoprofen Calcium sodium to categories not listed, and should be considered Meclofenamate Sodium piperacillin/tazobactam as the first line of prescribing. Tolmetin Sodium Amoxicillin/Clavulanate Potassium LOW COST GENERIC PREFERRED For benefit coverage or restrictions please check indomethacin your benefit plan document(s). This listing is revised Augmentin meloxicam periodically as new drugs and new prescribing LOW COST GENERIC naproxen kit information becomes available. It is recommended amoxicillin that you bring this list of medications when you or a dicloxacillin sodium CARDIOVASCULAR covered family member sees a physician or other penicillin v potassium ACE-INHIBITORS healthcare provider. GENERIC QUINOLONES captopril ANTI-INFECTIVES
    [Show full text]
  • Effect of Felodipine Against Pilocarpine Induced Seizures in Rats
    Int. J. Pharm. Sci. Rev. Res., 52(1), September - October 2018; Article No. 10, Pages: 54-60 ISSN 0976 – 044X Research Article Effect of Felodipine against Pilocarpine induced Seizures in Rats Osama Q. Fadheel 1, Faruk H. AL-Jawad 1, Waleed K. Abdulsahib 2, Haider F. Ghazi 3 1Pharmacology Department, College of Medicine, Al-Nahrain University, Baghdad, Iraq. 2Pharmacy department, Al- Farahidi University College, Baghdad, Iraq. 3Microbiology Department, College of Medicine, Al-Nahrain University, Iraq. *Corresponding author’s E-mail: [email protected] Received: 25-07-2018; Revised: 22-08-2018; Accepted: 05-09-2018. ABSTRACT Epilepsy is a standout amongst the most well-known genuine cerebrum issue, can happen at all ages. The examination was performed to investigate the conceivable antiepileptic impact of Felodipine against pilocarpine prompted seizure in male rats. The investigation did on forty male Wister rats similarly assigned to four gathering: (1) typical gathering (not got any medication). Gathering (2) negative control gathering (got just pilocarpine amid acceptance of seizure. Gathering (3) positive control gathering (Valproic corrosive gathering got 20 mg/kg orally twice every day). Gathering (4) Felodipine gathering (1 mg/kg got orally once every day). Rats of each gathering (aside from typical gathering) were infused intraperitoneal with pilocarpine hydrochloride (400 mg/kg) following 21 long stretches of tried medications organization orally. The mean beginning and term of seizure were resolved to assess the viability of tried medications and to contrast these impact and that of typical gathering and Valproic corrosive gathering. Additionally, neuroprotective impact (Neu N), NMDA receptor, Sodium diverts were estimated in all gatherings.
    [Show full text]
  • Summary of Product Characteristics, Labelling and Package Leaflet
    SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET 1 SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT /.../ 10 mg film-coated tablet /.../ 20 mg film-coated tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains 10 mg lercanidipine hydrochloride, equivalent to 9.4 mg lercanidipine. One film-coated tablet contains 20 mg lercanidipine hydrochloride, equivalent to 18.8 mg lercanidipine. Excipient with known effect: /.../ 10 mg film-coated tablet: Lactose monohydrate 30 mg Excipient with known effect: /.../ 20 mg film-coated tablet: Lactose monohydrate 60 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film--coated tablet /.../ 10 mg film-coated tablet: Yellow, round, biconvex 6.5 mm film-coated tablets, scored on one side, marked 'L' on the other side. /.../ 20 mg film-coated tablet: Pink, round, biconvex 8.5 mm film-coated tablets, scored on one side, marked 'L' on the other side. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications /.../ is indicated for the treatment of mild to moderate essential hypertension. 4.2 Posology and method of administration Posology Route of administration: For oral use. The recommended dosage is 10 mg orally once a day at least 15 minutes before meals; the dose may be increased to 20 mg depending on the individual patient's response. Dose titration should be gradual, because it may take about 2 weeks before the maximal antihypertensive effect is apparent. Some individuals, not adequately controlled on a single antihypertensive agent, may benefit from the addition of lercandipine to therapy with a beta-adrenoreceptor blocking drug, a diuretic (hydrochlorothiazide) or an angiotensin converting enzyme inhibitor.
    [Show full text]
  • Effect of Lacidipine and Nifedipine GITS on Platelet Function in Patients with Essential Hypertension
    Journal of Human Hypertension (2000) 14, Suppl 1, S91–S95 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh Effect of lacidipine and nifedipine GITS on platelet function in patients with essential hypertension MC Armas-Padilla1, MJ Armas-Herna´ndez1, R Herna´ndez-Herna´ndez1, M Velasco2, B Pacheco1, AR Carvajal1 and A Castillo-Moreno1 1Clinical Pharmacology Unit, School of Medicine, Universidad Centroccidental Lisandro Alvarado, Barquisimeto, Venezuela; 2Clinical Pharmacology Unit, Vargas Medical School, Central University of Venezuela, Caracas, Venezuela With the aim of evaluating the effects on blood pressure, Both drugs reduced systolic and diastolic blood press- platelet function and insulin sensitivity of the dihydro- ure at the same level, however there were observable piridines lacidipine and nifedipine GITS, a parallel dou- differences in the rate of reduction. The nifedipine GITS ble-blind study was carried out in a group of 20 patients reduced supine systolic blood pressure by 25 mm Hg in with mild to moderate essential hypertension. They the first week, while the lacidipine did so by 11 mm Hg. received a placebo for 4 weeks; then were divided at At the end of the study period nifedipine reduced supine random into two groups of 10 patients each. Nifedipine systolic blood pressure by 28 mm Hg and lacidipine by GITS, 30 mg and lacidipine, 4 mg, were given during 16 20 mm Hg. Heart rate was increased slightly but signifi- weeks of active treatment. Blood pressure and heart cantly in the nifedipine GITS group only in the standing rate were measured at the clinic in supine, sitting and position.
    [Show full text]
  • Dorset Medicines Advisory Group
    DORSET CARDIOLOGY WORKING GROUP GUIDELINE FOR CALCIUM CHANNEL BLOCKERS IN HYPERTENSION SUMMARY The pan-Dorset cardiology working group continues to recommend the use of amlodipine (a third generation dihydropyridine calcium-channel blocker) as first choice calcium channel blocker on the pan-Dorset formulary for hypertension. Lercanidipine is second choice, lacidipine third choice and felodipine is fourth choice. This is due to preferable side effect profiles in terms of ankle oedema and relative costs of the preparations. Note: where angina is the primary indication or is a co-morbidity prescribers must check against the specific product characteristics (SPC) for an individual drug to confirm this is a licensed indication. N.B. Lacidipine and lercandipine are only licensed for use in hypertension. Chapter 02.06.02 CCBs section of the Formulary has undergone an evidence-based review. A comprehensive literature search was carried out on NHS Evidence, Medline, EMBASE, Cochrane Database, and UK Duets. This was for recent reviews or meta-analyses on calcium channel blockers from 2009 onwards (comparative efficacy and side effects) and randomised controlled trials (RCTs). REVIEW BACKGROUND Very little good quality evidence exists. No reviews, meta-analyses or RCTs were found covering all calcium channel blockers currently on the formulary. Another limitation was difficulty obtaining full text original papers for some of the references therefore having to use those from more obscure journals instead. Some discrepancies exist between classification of generations of dihydropyridine CCBs, depending upon the year of publication of the reference/authors’ interpretation. Dihydropyridine (DHP) CCBs tend to be more potent vasodilators than non-dihydropyridine (non-DHP) CCBs (diltiazem, verapamil), but the latter have greater inotropic effects.
    [Show full text]
  • Evaluation of Therapeutic Drug Monitoring (TDM) on Older Antiepileptic Medications
    Available online a t www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2015, 7 (2):243-250 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4 Evaluation of therapeutic drug monitoring (TDM) on older antiepileptic medications Dayana Nicholas* 1, Azmi Bin Sarriff 2, Tharmalingam Palanivelu 3, Kenneth Nelson 4 and Samson P. George 5 1Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Bedong, Kedah, Malaysia 2School of Pharmaceutical Sciences, Department of Clinical Pharmacy & Faculty of Pharmacy, University Sains Malaysia, Penang, Malaysia 3Consultant Physician and Head of Department, Department of Medicine, Hospital Sultan Abdhul Halim, Malaysia 4Department of Pharmacy Practice, Faculty of Pharmacy, Grace College of Pharmacy, Kerala, India 5Drug Information Centre, Karnataka State Pharmacy Council, Bangalore, Karnataka, India _____________________________________________________________________________________________ ABSTRACT The Prospective study was conducted to evaluate the measure of Therapeutic Drug Monitoring (TDM) services on conventional antiepileptic drugs (AEDs) in 160 epileptic patients’ data of children and adults with both genders was on AEDs. The study results have shown 66 patients (50.38%), under subtherapeutic range on single AEDs with phenytoin and Na.valproate. In 160 patients, 13 of 98 (13.54%) adult patients received co-medication and 3 of 62 (6.25%) children with co-medications. Overall average (Vd) for carbamazepine in adult and children patients was found to be 78.25L which was higher than Vd for phenytoin (35.12L) and Na.Valproate (11.73L). The overall mean of clearance (Cl) for phenytoin (35.59L/hr) was found to be the highest, followed by Carbamazepine (3.81L/hr) and Na.Valproate (0.40L/hr).
    [Show full text]
  • Package Insert Template for Felodipine Extended Release Tablet
    PACKAGE INSERT TEMPLATE FOR FELODIPINE EXTENDED RELEASE TABLET Brand or Product Name [Product name] ER Tablet 2.5mg [Product name] ER Tablet 5mg [Product name] ER Tablet 10mg Name and Strength of Active Substance(s) Felodipine 2.5mg Felodipine 5mg Felodipine 10mg Product Description [Visual description of the appearance of the product (eg colour, markings etc) eg White, circular flat beveled edge extended release tablets marked ‘10’ on one side] Pharmacodynamics Felodipine is a vascular selective calcium antagonist which lowers arterial blood pressure by decreasing systemic vascular resistance. Due to the high degree of selectivity for smooth muscle in the arterioles, felodipine in therapeutic doses has no direct effect on cardiac contractility or conduction. Because there is no effect on venous smooth muscle or adrenergic vasomotor control, felodipine is not associated with orthostatic hypotension. Felodipine possesses a mild natriuretic/diuretic effect and fluid retention does not occur. Felodipine is effective in all grades of hypertension. It can be used as monotherapy or in combination with other antihypertensive drugs, e.g. ß-adrenoceptor blockers, diuretics or ACE-inhibitors, in order to achieve an increased antihypertensive effect. Felodipine reduces both systolic and diastolic blood pressure and can be used in isolated systolic hypertension. Felodipine maintains its antihypertensive effect during concomitant therapy with non-steroidal anti-inflammatory drugs (NSAID). Felodipine has anti-anginal and anti-ischaemic effects due to improved myocardial oxygen supply/demand balance. Coronary vascular resistance is decreased and coronary blood flow and myocardial oxygen supply are increased by felodipine due to dilatation of both epicardial arteries and arterioles. Felodipine effectively counteracts coronary vasospasm.
    [Show full text]
  • Potentially Harmful Drugs in the Elderly: Beers List
    −This Clinical Resource gives subscribers additional insight related to the Recommendations published in− March 2019 ~ Resource #350301 Potentially Harmful Drugs in the Elderly: Beers List In 1991, Dr. Mark Beers and colleagues published a methods paper describing the development of a consensus list of medicines considered to be inappropriate for long-term care facility residents.12 The “Beers list” is now in its sixth permutation.1 It is intended for use by clinicians in outpatient as well as inpatient settings (but not hospice or palliative care) to improve the care of patients 65 years of age and older.1 It includes medications that should generally be avoided in all elderly, used with caution, or used with caution or avoided in certain elderly.1 There is also a list of potentially harmful drug-drug interactions in seniors, as well as a list of medications that may need to be avoided or have their dosage reduced based on renal function.1 This information is not comprehensive; medications and interactions were chosen for inclusion based on potential harm in relation to benefit in the elderly, and availability of alternatives with a more favorable risk/benefit ratio.1 The criteria no longer address drugs to avoid in patients with seizures or insomnia because these concerns are not unique to the elderly.1 Another notable deletion is H2 blockers as a concern in dementia; evidence of cognitive impairment is weak, and long-term PPIs pose risks.1 Glimepiride has been added as a drug to avoid. Some drugs have been added with cautions (dextromethorphan/quinidine, trimethoprim/sulfamethoxazole), and some have had cautions added (rivaroxaban, tramadol, SNRIs).
    [Show full text]
  • Summary of Product Characteristics
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT <Invented Name> 10 mg/10 mg Film-coated Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 10 mg enalapril maleate and 10 mg lercanidipine hydrochloride. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet <Invented Name> 10 mg/10 mg film-coated tablets are white to off white, round, biconvex film-coated tablets approximately 9 mm in diameter. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of essential hypertension in patients whose blood pressure is not adequately controlled by lercanidipine 10 mg alone. Fixed combination <Invented Name> 10 mg/10 mg should not be used for initial treatment of hypertension. 4.2 Posology and method of administration Posology Patients whose blood pressure is not adequately controlled by lercanidipine 10 mg alone could either be titrated up to lercanidipine 20 mg monotherapy or switched to fixed combination <Invented Name> 10 mg/10 mg. Individual dose titration with the components can be recommended. When clinically appropriate, direct switch from monotherapy to the fixed combination may be considered. The recommended dose is one tablet once a day. Elderly patients The dose should depend on the patient’s renal function (see ‘renal impairment’). Renal impairment <Invented Name> is contraindicated in patients with severe renal dysfunction (creatinine clearance <30 ml/min) or in patients undergoing haemodialysis (see sections 4.3 and 4.4). Particular caution is needed when initiating treatment in patients with mild to moderate renal dysfunction. Hepatic impairment <Invented Name> is contraindicated in severe hepatic dysfunction.
    [Show full text]